Project Details

Novel Method Development for Discovering Biomarkers for Early Cancer Diagnosis

Generally, protein arrays and SEREX are used to discover autoantibodies. Although many autoantibodies are identified by using these methods, these autoantibodies cannot be validated and used for cancer diagnosis clinically.

Throughout this project a method is going to be developed for identification and routine screening of autologous antibodies which will be valuable for diagnosis and early diagnosis of cancer. As an innovative approach we are going to combine in-vitro translation with fully automated Wester Blotting. By this approach the identification and validation methods of autoantibodies are going to be identical  so that strongly suggest that the valuable antibodies in the identification step are going to remain valuable afrer validation step as well. 



PRZ BioTech Team has over 25 years of experience in biomarker discovery and validation
PRZ BioTech have extended experience in project development, management and performing value added R&D.
PRZ Biotech aims to be leader in development of novel and key technologies, kits, and services for cancer diagnosis in Turkey.